Bluejay Therapeutics has completed a sizeable third-round financing, raising $182 million that will be used for clinical trials of its drug candidates for hepatitis.
The proceeds are earmarked mainly for trials of BJT-778, its lead candidate for chronic hepatitis D virus (HDV) infections, but will also support earlier-stage hepatitis B virus (HBV) projects, according to the California-based biotech.
